P-oxooxazolidinylbenzene sulfonamides as antibacterial agents
Abstract
Novel p-oxooxazolidinylbenzene sulfonamides, such as ( l )-4-[5-(hydroxymethyl)-2-oxooxazolidin-3-yyl]benzene-sulfonamide, are useful as antibacterial agents. This application is a continuation-in-part of my copending application US.S.N. 327,583, filed December 4, 1981.

Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
10 claims: 10 independent, 0 dependent
- 1A compound of formula u 1 . ΙΊία ένωση του τύπου u M) whose R1 is -IS ^, -NiORgjR ^, -N, -IlhyH ^ -KXg, -I®1QX, -i 'Z or -H = 3 (O)nSsH9· Rg and R2 are independently H, alkyl of 1-4 G atoms or cycloalkyl of 3-8 atom C. R- is H, -CRg, -C (CH)mC-0H, -G-CH = GH-C-OH, «2 Μ) οπού τό R1 είναι -IS^, -NiORgjR^, -Ν , -ΙΙΗγϊΗ^ -KXg, -I®1QX, -i«Z ή -H=3(O)nSsH9· τά Rg καί R^ είναι ανεξάρτητα Η,άλκύλιο με 1-4 άτομα G ή κυκλοαλκύλιο μέ 3-8 ατομα C. θ τό R- είναι Η, -CRg, -C(CH )mC-0H, -G-CH=GH-C-OH, « 2 0- ^ a? · A:;0- ^Gος α;· α:;. Tj Tj I 7 ιύ R^ εί,ναι άρύλιο ή άλκύλιο μέ 1-12 ατομα G, τό R^ εΐναι Η,άλκύλιο μέ 1-5 άτβμα C, GH^OH, CHgSH,άρύλιο ή άραλκύλιο τά RQ καί Rg είναι ανεξάρτητα άλκύλιο μέ 1-4 άτομα G ή μαζί είναι I7 is R R εί, yes aryl or alkyl with 1-12 atoms G, R ^ is H, alkyl with 1-5 atoms C, GH ^OH, CHgSH, aryl or aralkylQ and Rg is independently alkyl having 1-4 G atoms or together -(0¾. -(0¾. R,o e is alkyl having 1-4 atoms C the X is C1 or Br the Z is a naturally occurring cation m is 2 or 3 n is 0 or 1 and b is 3, 4 or 5, τό R,o ε ίναι άλκύλιο μέ 1-4 άτομα C τό X είναι C1 ή Br τό Ζ είναι φυσιολογικά άνεκτό κατιόν τό m είναι 2 ή 3 τό η είναι 0 ή 1 καί τό β είναι 3, 4 η 5,
- 2A compound according to claim 1 wherein R = H. 2. Μία ένωση κατά τήν άξίωση 1 δπου τό R =Η. The ο
- 3A compound according to claim 1 wherein RjZliH 3. Μία ένωση κατά τήν άξίωσιν 1 οπού τό RjZliH
- 4The compound of claim 1 which is;4. *Η ένωση κατά τήν άξίωση 1 η οποία είναι ? » θυλο)-2-οξοοξαζολιδιν-3-υλ7-βενζολοσουλφοναμίδι »Thyl) -2-oxoazazolidin-3-yl7-benzenesulfonamide -405. A pharmaceutical preparation consisting essentially of a suitable pharmaceutical excipient and an antibacterially active amount of a compound of claim 1. -405. Φαρμακευτικό παρασκεύασμα ,πού άποτελεΐται βασικό άπό ένα κατάλληλο φαρμακευτικό έκδοχο καί μία άντιβακτηρικά δραστική ποσότητα μίας ένωσης κατά τήν άξίωση 1.
- 56. A pharmaceutical preparation consisting essentially of a suitable pharmaceutical excipient and an antimicrobial active amount of a compound of claims 2-4. 6. Φαρμακευτικό παρασκεύασμα πού άποτελεΐται βασικά άπό ένα κατάλληλο φαρμακευτικό έκδοχο καί μία άντιμικροβιακά δραστική ποσότητα μιας ένωσης άπό τίς άξιώσεις 2-4.
- 67. A method of treating bacterial infections in mammals comprising administering to the mammal an antimicrobial active amount of a compound of claim 1. 7. Μέθοδος θεραπείας βακτηριακών λοιμώξεων σέ θηλαστικά η οποία συνίσταται στήν χορήγηση στό θηλαστικό μιας άντιμικροβιακά δραστικής ποσότητας μίας ένωσης κατά τήν άξίωση 1.
- 78. A method of treating bacterial infections in mammals consisting of not administering to the mammal an antimicrobial active amount of mild compound according to claim 2-4. 8. Μέθοδος θεραπείας βακτηριακών λοιμώξεων σέ θηλαστικά η οποία συνίσταται αήν χορήγηση στό θηλαστικό μίας άντιμικροβιακά δραστικής ποσότητας μιδς ένωσης κατά τήν άξίωση 2-4.
- 89. Process for the preparation of compounds according to claim 1, which comprises:9. Μέθοδος παρασκευής ένώσεων κατά τήν άξίωση 1 ή οποία συνίσταται: ♦ I— (a) on the reaction of a compound of the formula: halogen-302 wherein Y is a substituent, containing acyl, with an "reagent" selected from a suitable HHRgR ^ or HN (0R2) R ^ amine, N azide ion, or hydrazine to form a compound of the formula ♦ I— (α) στήν άντίδραση μίας ένωσης τού τύπου: άλογόνο-302 δπου τό Υ εϊναι ύποκαταστάτης,ο οποίος περιέχει άκύλιο,μέ “ενα άντιδραατήριο,τό οποίο έκλέγεται άπό μία κατάλληλη άμίνη HHRgR^ ή HN(0R2)R^, ίόν άζιδίου Ν_, ή υδραζίνη οπότε παρασκευάζεται μία ένωση τοΟ τύπου R.-SO whose R1 = 1 ^^, N (OR2(B) the possible reaction of the product of step (a) wherein R ^ = NHg with a prepared halogen or a halogen and a base;R.-SO οπού R1 =1^^, N(OR2)R^, ή NHNHg’ (β) στήν ένδεχόμενη άντίδραση τού προϊόντος τοΟ σταδίου (α) δπου R^ = NHg μέ ένα προπαρασκευασθέν υποαλογονώδες ή μέ ένα άλογόνσ καί μία βά- -41c) in the possible reaction of the product of step (b) with (I) an adductive hypohalogen at pH of about 4-6 whereby a compound of the formula is prepared -41γ) στήν ενδεχόμενη αντίδραση τοϋ προϊόντος τοϋ σταδίου (β) μέ (I) πρόσθετο ύποαλογονώδες σέ ΡΗ περίπου 4-6 οπότε παρασκευάζεται μία ένωση τοϋ τύπου IjNSoXO having X = 01 or n (tJ) dialkyl thioxide SRgRg, whereby a compound of the formula is prepared IjNSoXO οπού Χ=01 η Βγ η (ίJ) θειοϋχο διαλκύλιο SRgRg,οπότε παρασκευάζεται μία ένωση τοϋ τύπου RgR9S = KSO2 (d) the possible oxidation of the product of step (c) (I) whereby: a compound of the formula RgR9S=KSO2 (δ) στήν ενδεχόμενη οξείδωση τοϋ προϊόντος τοϋ σταδίου (γ) (I!) οπότε παρασκευάζεται: μία ένωση τοϋ τύπου RgRgSsNSO RgRgSsNSO (e) the possible reaction of the product of step (a) with R ^ 'NRgB-j »' 2 'and R R-alkyl of 1-4 atoms 0 with a halo, whereby the compound is prepared. ε) στήν ένεδεχόμενη αντίδραση' τοϋ προϊόντος τοϋ σταδίου (α) δπου R^ « NRgB-j» ^2^2 καί R^- άλχύλιο μέ 1-4 άτομα 0 μέ ύποαλογονώδες,οπότε παρα· σκευάζεται ή ένωση. R1QXN-302 R1QXN-302 OH f) the possible reaction of the product of any of steps (a) - (e) with (ii) an acid chloride RgCOGl or anhydride (RgCOjgO whereby a compound of the formula is prepared ΟΗ στ) στήν ενδεχόμενη αντίδραση τοϋ προϊόντος οίουδήποτε άπό τά στάδια (α)-(ε) μέ (ϊ) ένα χλωρίδιο όξέος RgCOGl ή άνυδρίτη (RgCOjgO οπότε παρασκευάζεται μία ένωση τοϋ τύπου -42 ° C · co σ and m = 2 or 3, whereby a compound of formula O is prepared -42@c σ· co σ καί m = 2 η 3, οπότε παρασκευάζεται μία ένωση τοΟ τύπου I ^ -So g I^-SOg ο E-G-A-GO2H (Πί) ενα προστατευμένο άμινοξύ τοϋ τύπου I^-CHCOgH EGA-GO2H (III) is a protected amino acid of the formula I -CHCOgH HHCOO-T, wherein Y is a protecting group, such as tert-butyl, in the presence of a carbodiimide followed by a volatile acid, HX, whereby a compound of the formula is prepared HHCOO-T, οπού τό Υ είναι μία προστατευτική ομάδα,όπως τό τριτ.βουτύλιο,παρουσία ένός καρβοδι’ϊμιδίου κι έν συνεχεία ακολουθεί ένα πτητικό όξύ,ΗΧ, όπότε παρασκευάζεται μία ένωση τοϋ τύπου A * ot ot0 Abena R1 -3W - O Α*ήχβ ot0 Αβήνα R1 -3¾ —\Ο
- 910. Method of separating 3- <paivu \ apiVo ~ j consisting of reaction of racemic "l-MlAHATAPXHjg _C, - ' 10. Μέθοδος διαχωρισμοϋ τής 3-<paivu\apiVo~j οποία συνίσταται, στήν άντίδραση τής ρακεμυ ” l-MlAHATAPXHjg _Γ, — ' 0C0 — CH-NH £ x J or 1 g of imino-1,2-propanediol with about 5 g -6 g% optically active almond acid, whereupon the salt is obtained, and then the reaction is taken with a base of salt. 3-Phenylamino-1,2- ------- -------------- Propanediol, enriched with one antimatter. 0C0—CH-NH£x J > <ι ιΐ /&/ιόλης ,ή * γΖ ιμινο-1,2-προπανοδιόλης μέ περίπου 5θ-6θ γρ/ρια% οπτικά ένεργοϋ άμυγδαλικοϋ όξέος, οπότε λαμβάνεται τό αλας, jiaί κατόπιν στήν άντίδρασιν τοϋ αλατος μέ μία βάση οπότε λαμβάνεται η 3-φαινυλαμινο-1,2- -------—------------προπανοδιόλη,έμπλουτισμένη μέ τό ένα έναντιομερές.
- 1011. The method according to claim 10 wherein the optically active almond acid is 1-almond acid and the product, 3-phenylamino-1,2-propanediol is enriched in the right-handed (b) -enantiomer. 11. ‘Η μέθοδος κατά τήν άξίωση 10 οπαυ τό οπτικό ενεργό άμυγδαλικό όξύ εϊναι τό 1-άμυγδαλικό όξύ καί τό προϊόν, 3-ψαινυλαμινο-1,2-προπανοδιόλη εϊναι έμπλουτισμένο στό δεξιόστροφο (β)-έναντιομερές. "0, what a precise translation of the attached English original “0,τι ακριβής μετάφρασις του συνημμένου ’Αγγλικού πρωτοτύπου.πζ
Independent claims10
351 paragraphs in 37 sections, as filed
Title £ -oxooxazolidine nyl £ enzol-sulf2thammonium_san_bacterial_ |
£ ^ D ^ D_l! 3i_ £££ H £ ®2] 5 £
New p-oxoazolidinylbenzenesulfonamides, such as (1) -4- / 5 (hydroxymethyl) -2-oxoazazolidin-3-yl7-benzenesulfonamides, are useful as antibacterial agents.
This announcement is a partial continuation of my concluding statement US3.N. 327,583, filed on December 4, 1 981.
theory of the invention
U.S. Patent 4,128,654 to FUGITT et al., I describes, inter alia, compounds of the site:
<img file="GR77795B_D0001.tif" />
<img file="GR77795B_D0002.tif" />
where
A = RS (0)<sub>n</sub>*
X = 01, Bir or F *
R = th '^ 3' alkyl °; and n = 0, 1 or 2 '
The compounds are described as useful for controlling fungal and bacterial diseases in plants.
UK patent 2005-151 by DBLANDE describes the following compound as antidepressant:
<img file="GR77795B_D0003.tif" />
<sup>0H</sup>3<sup>3</sup><O
<img file="GR77795B_D0004.tif" />
OH
U.3. U.S. Patent 4,340,606 9 describes antibacterial agents of the general formula
-3 degrees
R<sub>1</sub> = CHj, C<sub>2</sub>H<sub>5</sub>, OF.<sub>2</sub>H, GF<sub>3</sub> or CFgCFgH * et al
X = 0R<sub>2</sub>.
Summary of the Invention 2 * The invention relates to novel compounds of the formula I.
(i)
ORc where
R<sub>t</sub> is -KR ^, -liCORg)! ^, -Ny -HHNHg, -NXg, -1®<sub>1</sub> θX, -HXZ or -N = S (0)<sub>n</sub>E<sub>8</sub>E<sub>9</sub>·
R<sub>2</sub> and R ^ are independently H, alkyl with 1-4 atoms C or cycloalkyl with 3-8 atoms C ' <sub>θ θ θ</sub>
Rp is H, -OR ,, -G (OH_) C-OH, -G-GH = GH-G-OH, θ ° <sup>m</sup> o the sf- rf- .at · σ o<sub>2</sub>h
0<sub>2</sub>THE
COgH or -C-CH-R; 1¾ Rg is aryl or alkyl with 1-12 atoms G; yr is H, alkyl with 1-5 atoms G, GHgOH, GHgSH aryl or aralkyl R<sub>8</sub> and Rg is independently alkyl having 1-4 G atoms or together
- <° h<sub>2</sub>> „The R<sub>1O</sub> is alkyl having 1-4 atoms C * X is C1 or Br is Z is normally cationic m is 2 or 3 is 0 or 1 and p is 3, 4 or 5,
<img file="GR77795B_D0005.tif" />
-4 and their pharmaceutically acceptable salts.
Experimental results show that compounds of the formula I are useful for the alleviation of bacterial infections in mammals. The invention therefore also contains pharmaceutical preparations containing compounds of the formula I and methods for the use of these compounds in the mammals.
They are preferred because of their high antibacterial activity those compounds, independently of which R R is H and
KHGH ^ is particularly preferred for its high antibacterial activity of compound (ΐ) -4 - / "5- (hydroxymethyl) -2-oxooxazolidin-3-yl) -benzenesulfonamide.
Aryl aryl * as used in the definitions of substituents Rg and R; Suitable aryls include radicals of monocyclic compounds such as benzene, pyridine, pyrimidine, pyrazole, furane, triazine, thiophene, thiophene, thiophene, thiophene, thiophene, thiophene. Roots of polycyclic compounds such as diphenyl and terphenyl such as and of concentrated polycyclic compounds, such as naphthalene, carbon, phenanthrene, quinoline, isoquinoline, acridine, diphenyl, carnitine, benzene, nazine
Each of the aryls may optionally be substituted at each position by one or more substituents, including but not limited to P, Cl, Br, SOg, C 1-6 -alkyl or alkoxy, OH, CP ^, GN, GOg (G ^ -G ^ -alkyl) or S (0) CH ^, wherein cf = 'O, 1 or 2. Preferred aryl substituents are pyridine, thiophene, furane, pyrrol and benzene, optionally substituents / me the aforementioned substitutes.
f / z '• -u.
If- / W. > -t.
n'- 5'0S aralkyl which is used in the definition of R? comprises any alkyl preferably containing 1-4 G atoms, which is substituted with any of the above aryl substituents. Physiologically unsubstituted cations (Z), include alkali or alkali ions, such as K, M ^ *♦, Ga * *, Li *. Other suitable ions are known to those skilled in the art.
Detailed_content_2_of_02yourseconds
Composition Compounds of formula I with R ^ <sup>=</sup>And R ^ or NiORgjR ^, where
V represented by formula Ia can be prepared as shown in Figure 1.
<img file="GR77795B_D0006.tif" />
The OH group of 5-hydroxymethyl-3-phenyl-2-oxazolidinone (ΐΐ) is substituted if this or the compound is boiled with a reagent that will introduce an acyl, preferably an alpha-halogenated alkanol. Suitable reagents these include trifluoroacetic anhydride, dichloroacetyl chloride, dichloroacetic anhydride, trichloroacetyl chloride, and trichloroacetic anhydride.<sup>The</sup>0. This step should be solvent-free or with any inert hydrocarbon chlorohydrocarbon solvent.'0 formed by lactobacilli.
- see with a halosulfonic acid, such as chlorosulfonate or fluorosulfonate, at a temperature of 3O-4 ° C, whereby the sulfonyl halide of formula IV is obtained. This step is also precipitated without solvent, in chlorinated hydrocarbons, such as CHCl2, GH2Cl2 or CCl2. This product was then dissolved in a solvent, such as tetrahydrofuran ether, dioxane, 1,2-dimethozyaithanio, dimethylformamide, dimethylacetamide or urea derivative and reacted with the appropriate amine, HNRgR ^ or IiizOi ^) ^ 'at a temperature from -20 ° C to 30 ° C, whereby the compound of formula Ia is obtained.
Compounds of formula I, wherein X<sup>=</sup>Oh and so <sup>π0</sup>They are represented by the formula Ib can be prepared for sulfonyl halide IV
V is reacted with NaN 2 or EN 2 in acetone-C 0, as shown in Fig. 2. Suitable solvents include acetone, lower ketones
boiling point, such as methylthio-ketone, diethyl ketone and cyclopentanone, ethers and bipolar aprotic solvents.
THE
IV
YN, or YN,
N.<sub>3</sub>-3°<sub>2</sub>
<img file="GR77795B_D0007.tif" />
The azides Ib as the hydrazides Ig of this invention can also be prepared according to Figure 3:
<img file="GR77795B_D0008.tif" />
OH
MO,
X!
IaCBgsRy & k
Sulfonyl halide IV reacts with hydrazine, thereby preparing •,>> '/ tf; * * * is the hydrazide Ig. This can then be reacted with a nitride v / j.
such as NO in dilute bicarbonate and to give the same formulation as can be recovered with any of the Trisodiodines, whereby syslfonam is obtained (including 1a. Inappropriate reduction methods including with l'Or in one whole of the hydrogel, hydrolyzate;
The compounds of the intermediate where tt<sub>c</sub>-6 '£. r.<sup>r</sup> CR = 13.3, 17 = 3; G) R-.H 'm' p 'pvc' 4 preparations-cOV as shown in Figure 4:
£ 4: <sup>i</sup>
H<sub>2</sub>NS0 2Ό- ”° subel, onyx (oct)
<img file="GR77795B_D0009.tif" />
= straight / X.
OH
Ia (R.<sub>2</sub>= R<sub>3</sub>= H)
THE
<img file="GR77795B_D0010.tif" />
-8—
Halosulfonamide ID can be prepared directly if a sulfonamide 1a is reacted with a halogen and a base such as NaOH or with a preparated halogen, such as NaCl or Ca (0 C)<sub>2</sub>· To obtain N, N-dialisulfonamide the pH is adjusted to 4-8. Methods for adjusting the pH include adding CH2 COOH, 00<sub>2</sub> or high inorganic acid.
The sulphilimines can be prepared from the halosulfonamide LS reacted with a 3RgRg dialkylsulfide, or dimethylsulfide, trimethylenesulfide, methylethylsulfonyl or tetrahydrofolate. Oxidation of sulfilimines by e.g. hypochlorite or post-chloro-hyperbenzoic acid, gives sulfoximines Q.
Compounds of the invention which R ^ = HR ^ qX can be prepared
MBB as shown in Figure 5 by reaction with a halogen.
<img file="GR77795B_D0011.tif" />
hypoglycemic h<sub>2</sub>The
OH
H<sub>1o</sub>XH30<sub>2</sub>- <Q> -H \ O
OH
Various simple esters of this invention represented by the locus can be prepared as shown in Figure 6 by reacting a compound of formula Ia-In with an appropriate acyl chloride or anhydrous acid or anhydrous acid; The preferred solvent is either pyridine or other solvents of the pyridine class, although in many cases no solvent is required.
RgOOCl tt η
(r<sub>6</sub>co)<sub>2</sub>o
<img file="GR77795B_D0012.tif" />
Rj-soa
OH
-9 Many simple esters can also be prepared if a compound of the formula V is halosulfated as shown in Figure 7; No solvent is required; other solvents may be used inert to halosulfonic acid. The sulfonyl halide VI antiserum product: with NH 2 or with a suitable amine or azide or hirazine as in Figures 1, 2 and 3, wherein the ester of formula II is obtained.
Ha1-30, H
Hal-SO,
OCOR ..
n
V- OCOR,
VI
HHRgR ^ ». HNCORgjRj
OCOR,
Rj <sup>3</sup> KRgR ^
NINE<sub>2</sub> or RiORgjRj * The first substance V may be prepared from 5-hydroxymethyl-3-phenyl-2-oazazolidinone, as shown in Figure 8.
II based on anhydride
Other esters of this invention, Ik, can be prepared as shown in Figure 9, if an alcohol is reacted with a suitable anhydride:
& 5ESL9
C.<sup>THE</sup>2 ^> L '"" C
1a-In whose A = -OH = GH-, [O
OH
<img file="GR77795B_D0013.tif" />
-10Cc · OC * CX <sup>and</sup> is 2 or 3,
Suitable solvents are weak bases of the pyridine class and an appropriate temperature range for the reaction is about 3 ° -115 ° C;
The products obtained from the methods described hereinabove (Ia-Im) above are racemic mixtures, i.e., 50: 50 mixtures of (♦) and {-) - antimers. The synthesis of optically active compounds can be reduced<sup>w</sup> "Using as the starting material in Scheme 1, the compound 1-5-hydroxymethyl-3-phenyl-2-oxazolidinone (IIIa). This or the starting material can be obtained from the desulphurization of 1-3- / ~ (4-methylthio). ) -phenyl7-5-hydroxymethyl--2-osazolidinone (VII), as shown in Figure 10,
Figure 10
<img file="GR77795B_D0014.tif" />
,. , 1-isomer
1-isomers
A preferred method for the preparation of 1-5-hydroxymethyl-3-phenyl-2-oxazolidinone (Ia) is shown in Figure 11,
<img file="GR77795B_D0015.tif" />
-11 * Aniline in a 2-10 molar excess with glycidol. Excess aniline is removed by distillation and or (3 g) -3-phenylamino-1,3-propanediol is distilled off under reduced pressure. It is separated by combining with about 4 g-S0 molecular per cent solution of 1-amygdalic acid in CHGlH or GH .GN. The desired salt is crystallized and can be purified by recrystallization from GHGl2 or GH2GN. (3) 3-Phenylamino-1,3-propanediol can be isolated by reacting with a base. The salt is dispersed in HgO, the pH of the mixture is adjusted to 8-1 ° C, the mixture is saturated with NaCl and then extracted continuously with CHgGl2. Alternatively the salt is dissolved in a mixture of L2O-alcohol and passed through a strong base. In either case the precursor extract or eluent of the column is concentrated leaving either (<I) -3-phenylamino-1,3-propanediol. This product is then antiserum, with diethyl carbonate (others esters such as dimethyl- or diphenylcarbonate) in a polar solvent such as 1,2-dimethoxyethane, using CH2 Cl2 as catalysts. The product is isolated by concentrating the solvent, diluting with H2 O and slightly GH2 GOOH, and washing with HgO. The product may be purified by recrystallization from 950 ethanol or CH 2 CN. '<sup>,</sup>Using the 3-almond acid in this procedure the 3-isomer of 5-hydroxymethyl-3-phenyl-2-oxazolidinone can be obtained.
"Another route for the optically active compounds of the invention comprises carrying out the first reaction of Figure 11 by employing / activating glycidol preferably R-glycidol, whereby the direct or optically active base is obtained.
1-5-Hydroxymethyl-3-phenyl-2-oxazolidinone / (IIa) Corexyl, prepared from (H) - (->) -1-benzylglycerol ^ 3 GOTO, M.F. HIRAMA, and 0GA3AWARA, HSTEROCYCLBS, 16,
-12C tosylation: ·, (p-toluenesulfonyl tertiary ester thus kJ) -tosyl ester (V
Z.-OC-1-Nyl-4-methylbenzenesulfonomide in particular XIX. Toxic byproduct (IX)
Chloride in a pyrene: · C111) with the colloidal life with a dipolar aprotic solvent; with the Sodium radical of sodium naphthalenic acid, where it is rubbed with rv-Zirconium diethyl ester or the other catalytic amounts of CH2 OTe, whereby it is dried until this series is shown in Figure 12:
Clone X any of the esters esters in the presence of miR-epimeric 1-isomer.
- Step 72:
<img file="GR77795B_D0016.tif" />
<img file="GR77795B_D0017.tif" />
(B.) - isomerase 30 I *
<img file="GR77795B_D0018.tif" />
jesus; l · ..; εύ εύ εύ έ γ γ::
m - r '- - V. e-xz' / Xw -, · · in up or subtractions of Figure 1;
or 13:
'ΐ<sup>i</sup>2<sup>5</sup>- (IX.<sup>N.</sup>
THE.
R<sub>?</sub>-CHC0<sub>2</sub>H
NHCOO-t-Bu
XI
Ia-Ih a carbodiimide, c
e.g. <C> - N = C = N—
<img file="GR77795B_D0019.tif" />
0C0-CHNHC00-t-Bu
I.
R,
XII Acid
HX <sup>R</sup>1°2<sup>S</sup>
L.
N O
M_
0C0-CH-NH<sub>3</sub><sup>+</sup>X
Im
<img file="GR77795B_D0020.tif" />
L.
-14Alcohol reacts with the appropriately protected amino acid (XI) in the presence of a carbohydride such as dicyclohexylcarbodiimide. range from O-1 ° C The filtered product (XII) is treated with a volatile acid (e.g.
CF-GOOH) at 0-50 ° C. After removal of the acid, for example by distillation in vacuo, the ester 1 remains in the form of the acid salt (e.g. salt with CFjCQOH). This can be released as an amine after treatment with a base. Treatment of this amine with the appropriate acid gives the desired salts, such as hydrochloride, phosphate, sulfate, acetate and benzoate.
The acidic compounds (Ik) of this invention form salts with various inorganic and organic bases, all of which are salts within the scope of this invention. Such salts include alkali salts such as sodium or potassium, ammonium salts, alkali salts such as calcium and magnesium, organic base salts such as the following aliphatic amines, benzylamine, dicyclohexylamines and bicyclohexylamines.
<img file="GR77795B_D0021.tif" />
<img file="GR77795B_D0022.tif" />
-15Example 1
4-Z '5- (' Hydroxymethyl) -2-ozozazolidin-3-ylbenzenesulfonamide (R<sub>1</sub> = NH<sub>2</sub>, R.<sub>5</sub>= H) <sup>u</sup>Sva solution of 247.3 g (ΐ.00 g / l) of 1 L-phenyl-4-methylbenzenesulfonamide, containing 20 g of 1,4-cyano-bicyclo / 22.2.27 octane (DABC0) in 95 g / ml. dimethylformamide (BI; 3 *) is stirred and heated in a nitrogen atmosphere, while a solution of 7 ml is added. fresh distilled glycidol in 70 ml IMI, within 2 hours. The heating was continued for one hour and 4 minutes, and then a further 33 ml of glycidol was added at 33 h.K.MDF for one hour.
Heating is continued for 5 1/2 hours. The mixture is left in 4 liters. cold HgO (in the presence of some ice) and the product N- (2,3-dihydroxypropyl) -4-methyl-4-phenylbenzenesulfonamide crystallize. This is filtered off and washed thoroughly with cold HgO, yielding 348 g. mp 91-1-4 ° C and then recrystallize from 700 ml of toluene, yielding 312 g. m.p. 100 ° C-105 ° C.
250 g of 40% sodium suspension in mineral oil are added to a solution of 600 g of naphthalene in 1.8 L of 1,2-dimethozoate (glyme) which is stirred under nitrogen and maintained at a temperature of 20 ° C. <sup>n</sup> »
0. After all of the sodium was added, the mixture was stirred for 20 minutes and then 3 g of 5 g were added. N- (2,3-Hydroxypropyl) -4-methyl-4-phenylbenzenesulfonamide through a solid addition funnel, while the temperature is kept below 35 ° C. After all the solid is added, the mixture is stirred for 1 hour. The color of the solution turns dark green or mauve yellow. Then concentrate HCl is added, until the solution becomes strongly yellow. The mixture is extracted 2 times with toluene, and then 3 times with hexane, transferred / nitrogen \ to remove the hexane. , is saturated with NaCl and after NH 3. The product is extracted with CHgClg and in vivo<sub>2</sub>so<sub>3</sub>the filtered condensate is then
<img file="GR77795B_D0023.tif" />
-153-phenylamino-1,2-propanediol, pale yellow oil.
“A mixture of 83.6 g. (0.5 g) 3-phenylamino-1,2-propanediol, 250 ml. 1, 2-dimethoxyethane and 61 ml. of diethyl carbonate are boiled under an atmosphere of nitrogen. The virus mixture is cooled, stirred with 0 and filtered, whereupon they are obtained
41.1 g of 5- (hydroxymethyl) -3-phenyl-2-oxazolidinone, m.p.122–4 ° C.
41.1 g of recrystallized from 100 ml of absolute ethanol to give 38.0 g. m.p. 125t5-126 ° C. An additional 25.3 g (m.p.
124.5-125 ° C) is obtained from aqueous filtrates, concentrated, and recrystallized from ethanol.
A mixture of 25.3 g. 5-phenoxymethyl) -3-phenyl-2-oazazolidinone and 100 g. The trifluoroacetic anhydride is boiled under water for 1 hour. The solid is completely dissolved. The mixture is then concentrated in vacuo to obtain. 41 g of oil, which is crystallized during the stay. The product is used without further purification.
About 250 ml Chlorosulphonic acid is stirred well in a flask under nitrogen,.<sub>:</sub>---.--2__^___.<sub>></sub>while the above product is added within 15 minutes. The mixture is not cooled and the temperature is maintained at 3 ° -40 ° C. The solid is dissolved by heat dissolution and HG1. The mixture is stirred at room temperature for 1 hour 20 minutes. ice-proof. The product (4H) -4 - / - 5- (trifluoroacetozymethyl) 2-oxoazazolidin-3-yl) -benzenesulfonyl chloride, is crystallized, filtered and washed thoroughly with cold IC50 and dried.
The product is then dissolved in tetrahydrofuran and stirred in an ice bath, with 18 ml added. Concentration and filtration give 24 bw of above compound, m.p. 1 54-6 ° C.This is recrystallized from OH, ON / so - Cyanide
15.8 g m.p. 167-8 ° C. /
-17Example 2
1-4 - / "5- (hydroxymethyl) -2-ozozazolidin-3-yl) -benzenesulfonamide _________________ 15 ^ 3 ^ 2 ^ - 5 ----__________________________________
300 g of RANEY nickel catalyst are added with stirring to a solution of 40.4 g of RANEY. (0.169 g) 1-3 - / '(4-methylthio) phenyl7-5-hydroxymethyl-2-oxazolidine in 500 ml. of ethanol and the resulting mixture is boiled for 1 hour. "3 The sample of the reaction mixture is controlled by NMR showing removal of the -3GHg group. The solution is then filtered and the reaction mixture is extracted repeatedly with boiling alcohol. , whereupon 32.5 g of 1-5-Hydroxymethyl-3-phenyl-2-oxazolidinone are obtained, mp.134-6 ° C. The product was recrystallized from 115 ml of absolute ethanol, each time taking 32.5 g. white crystals. 138-: 139 · 5 ° C. The product is recrystallized once more from 106 ml of absolute ethanol, whereby 28.9 g of the product is obtained mp 139-140 ° C,
Mixture of 28.7 g (0.148 g / l) 1-5-hydroxymethyl-3-phenyl-2-oz. " zolidinone in 100 ml Boil trifluoroacetic anhydride until the solid dissolves. The mixture is concentrated in vacuo and the residual oil is added to 200 ml. n-chlorosulfonic acid, while the mixture is kept at a temperature below 30 ° C. The mixture is then stirred at room temperature for 2 1/4 hours and then ice-cooled. trifluoroacetoxymethyl) -2-oxooxazolidin-3-yl) -benzenesulfonyl chloride) is filtered off and washed with HgO and then added to a 60 ml mixture. of concentrated NH ^, in 300 ml. THF while the temperature of the resulting mixture is maintained at -10 ° to 0 ° C. The resulting mixture is stirred for 15 minutes at 0 ° C and for 3 ° minutes without external cooling. The mixture is then concentrated under cooling to room pressure. The THF was removed and diluted with - - L- * The product was washed with HgO and filtered to obtain / 33ml over compound, mp.182-4 ° C. (At 1 58 ° C, 1 Hz-mmx rk Y-u * 4 hz -? '/, Is observed.
ZI-L
- - gXJ -
-18 ° C, amorphous). This is recrystallized from CH ^ QN and obtained,
25.5 g; 184.5-185 ° C.
Example 3 (c) -N, t-dimethyl- and (c) -timethyl-4 - / "5- (hydroxymethyl) -2-oxooxyazidin-3-yl) -benzene sulfonamide; RHGH ^, R ^ = THE).
A solution of 2.72 g. (0.01 g) (3 g) - / - 5- (Hydroxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonamide in 50 ml of dry dimethylformamide (DME), containing 5 g. anhydrous K.<sub>2</sub>Is stirred at 60 ° C while 0.62 ml of iodomethane is added to 10 ml. >> 3..
From the moment of addition the mixture is kept at 60 G for 1 hour, then concentrated in vacuo to distill the DKT. The residue (3.7 g) is taken up in dimethylsulfoxide and chromatographed at 3 · 0.<sub>2</sub> , whereby one of the first fractions is obtained 0.65 g. (& Quot) -N, Dimethyl-L4- / 5- (hydroxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonamide, m.p. 174-6<sup>THE</sup>0 · Run a second fraction of 1.05 g. (<&) - H -methyl-4 / - 5- (hydroxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonamide, m.p.
164-166 ° C, also obtained.
Example 4 (<h.) - 4- ^ 5 - (hydroxymethyl) -2-oxoxazolidin-2-ylbenzenesulfonylazide (R<sub>1</sub> -N<sub>3</sub>, R.<sub>5</sub>= H>
“A solution of 10 g. Yes in 20 ml. The H2 O was added to 200 ml of analytical grade acetone and then cooled to -5 ° C. (<Al) -4 - / "5- (trifluoracetosymethyl) -2-ozoazazolidin-3-yl7-benzeneU sulfonyl chloride (prepared as in Example 1) is added to the solution while the temperature of the mixture is kept below 0 ° C. After stirring the mixture for one hour, leave overnight to dry. The acetone is removed in vacuo, H2 O is added and washed with H2 O. 12.8 g are obtained. f.108; / 11-L<sup>2</sup> This product is stirred with 250 ml. GH-GN at 25 ° C and a ratio of? n * '*
I T I K), f Z '' I / V remove insoluble. CH ^ GN is concentrated solid, crystalline;
<img file="GR77795B_D0024.tif" />
The pro-19n product is filtered off to give 12.3 g. This product is recrystallized from ethyl acetate and 6.0 g of the above compound is obtained, m.p. 112-3 ° C.
Example 5
1-4 - / '5- (hydroxymethyl) -2-oxooxazolidin-3-ylZ-benzenesulfonyl azide (R<sub>1</sub> = N<sub>?</sub>, R.<sub>5</sub> = H)
5'n 5 g solution; NaNl in 10 ml. H2 O is added to 100 ml. acetone analytical grade and then cooled to -5 ° C. 7 g 1-4 - / "5- (trifluoroacetoxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonyl chloride (prepared as in Example 3) is added while the temperature of the mixture is maintained at -5 to 0 ° C." an-. for one hour at 0 ° C and then overnight or acetone is removed in vacuo. HgO is added and the solid is filtered off and washed with HgO, to obtain 4.8 g. m.p. 13b-8 ° C. This solid is recrystallized from ethyl acetate, whereby 4 g above compound is obtained, mp.137-8 ° C.
Example 6
1-4 - / * 5- (hydroxymethyl) -2-oxooxazolidin-3-yl7-N-methyl-benzenesulfonamide (R<sub>1</sub> = EHGH ^, R<sub>5</sub> = H)
Make a 10 ml solution. of methylamine in 200 ml of tetrahydrofuran dry (THE) is stirred while 6.3 g of 1-4 - / "5- (trifluoroacetozymethyl) -2-oxoazazolidin-3-yl7-benzenesulfonylhydrochloride is added. 0<sup>?</sup>the shorter during this addition and then allowed to warm to room temperature while stirring overnight. After the THC was removed in vacuo, HgO was added and a white solid was filtered and washed with H2O4. m.p. of product, mp.137-142 ° C. Recombinant? β? p? CH5 CN gives 3-83 g. of the above compound, m.p. 137-138 / 0.2 ''
-20Example 7
Using the method of SdS, one can prepare S (S) _4- (5-Hydroxymethyl) -2-oxooxazolidin-3-yl7-4-n-butyl-benzenesulfonamide (R = = HH-n-C1 H2), R ^<sup>= H</sup>) using® 4 ml of c-butylamine instead of methylamine.
Example 8
Using the method of SdS, one can prepare (S) -R, N-n-dibutyl-4- / 5- (hydroxymethyl) -2-oxoazazolidin-3-yl7-benzenesulfonamide (H 2 N 2 -C 2 H) ^ »R ^ <sup>S</sup>H). using 5.5 ml. di-n-, butylamine, instead of methylamine.
Example 9
1-4 - / "5- (hydroxymethyl) -2-oxooxazolidin-3-yl7-N-cyclopropyl-benzenesulfonamide (R2 -NH R2)<sup>=</sup>H)
A solution of 6 ml. of cyclopropylamine in 5 ml of tetrahydrofuran is stirred in a trough, while the thermocl. maintained below 30 ° C, and 9.3 YP · 1-4- / ~ 5- (trifluoroacetoxymethyl) -2-ozozazolidin-3-yl) -benzenesulfonyl chloride (see par. 2) was added. The mixture was stirred for one hour, The tetrahydrofuran is removed in vacuo, and the residue is diluted with HgO, acidified with inert HCl. The solid is filtered off, washed with HgO and dried. The yield of the above compound is 7 -0.06 g. m.p. 129-147 ° C. Recrystallize from 30 ml of CH 2 OH, to give 2.0 g. c, m 161 ° 3-163.4 ° C.
Example 10
1-4-*/<sup>-</sup>5- (Hydroxymethyl) -2-oxoazazolidin-3-yl7-N-methosbenzenesulfonamide (R<sub>1</sub> = NH0CH ^, R<sub>5</sub>= H)
A solution of 5 ml. methoxyamine (O-methylhydroxylamine) in 50 ml. Tetrahydrofuran is stirred and cooled to 10 ° C, especially when a solution of 4.4 is added within 15 minutes.
y V '/ (W) (trifluoroacetoxymethyl) -2-oxoazazolidin-3-yl) -benzenol.ylphonylchlM-21i (see par. 2) in 20 ml. tetrahydrofuran. Separate white solid. The mixture was allowed to warm to room temperature, filtered and concentrated to obtain a colorless gum. This (4.5 g ·) was chromatographed using WATER Go PREP — 500 with a mixture of 45% GH ^ GN, 55% Gi ^ Glg solvents. The 5th fraction (1.8 g) was crystallized from ethyl acetate, yielding 1.04 g. of the above compound, m.p. 129.0-131.5 ° C. Boil with 13 ml of ethyl acetate, cool and filter to obtain. <sup>n</sup>.73 gm 130-132.5 ° C;
Example 11 (d1) -N, N-dichloro-4 - / ** hydroxymethyl) -2-oxooxazolidin-3-yl) -benzenesulfonamide (R2 sNGlg, R2) <sup>=</sup>THE) ·
2 g (<R) -4 - / ”5- (Hydroxymethyl) -2-oxooxazolidin-3-ylbenzenesulfonamide in a 10 ml mixture. HgO and 5c mL. CHgQl2 is cooled (ice bath and 27 ml of 5.25% NaClO solution added (CL0R0X). - The solid is completely dissolved and formed. 121.5-123 ° C (dec.) Further 1.24 g was insoluble solid and had this infrared spectrum with the above sample.
(ΐ) -N, N-dichloro-4 - / "5- (hydroxymethyl) -2-oxoazazolinoyl-3-yl7-benzenesulfonamide _ _ __ __ _" A suspension of 1.00 g. (ΐ) -4 ° C 5- (Hydroxymethyl) -2-oxoazazol- .. din-3-yl7-benzenesulfonamide in 1 ml. Stirring is stirred in an ice bath while 13.5 ml is added. 5.25% Halogen solution (GL0ROX). Separate it-
<img file="GR77795B_D0025.tif" />
solution is slightly acidified by adding acetic acid. They are like white crystals, (1.24 g) mp.124.5-125
Example 13 (J1) -N-Chloro-4- / 5- (hydroxymethyl) -2-oxoazazolidamide, sodium salt (R = NGlNa, Re <sup>=</sup>Holsulpho-222.0 g (<1 g.) - 4 - / ”5- (Hydroxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonamide is stirred in 10 ml. HgO in a bath, with 15 · 5 ml added. of 5.25% NaCl solution (GLOROX). The solid is dissolved and then crystals are separated. Filter and wash with a small amount of cold HgO and dry. The yield of the above compound is 1.98 g. (splits when heated above 158 ° C). Example 14 (1) -N-Chloro-4 - / "5- (hydroxymethyl) -2-oxooxazolidin-5-yl7-benzenesulfonamide, sodium salt ________________________________________________ g. (ΐ) -4 - / ”5” (hydroxymethyl) -2-oxoazazolidin-5-yl7-benzenesulfonamide in 1 ml. The H2 is stirred in an ice bath while being added
6.5 ml NaClO (CLOROX 5.25% NaCl). The solid is dissolved and then a white solid crystallizes. The product is filtered and washed once with a small amount of ice-H2 O (1.15 g), mp L5-7 ° C;
Example 15 (db.) -N- 4- "4- / 5- (hydrosymethyl) -2-oxoazazolidin-3-yl7-phenylsulfonyl |
3/3-dimethylsulfonylamine ______________ “A suspension of 2.00 g. (3H) -4 - / '5- (hydroxymethyl) -2-oxoazazolidin3-yl) -benzenesulfonamide and 10 ml. H2 O is stirred and 11.5 g are added; 5.25% NaClO (C10HQX). Almost all or raw material dissolves. Filter the solution and add 25 ml. ethanol, followed by 10 ml. The mixture is stirred well for 30 minutes and then concentrated to a colorless glassy product. It is dissolved in OH 2 GN and chromatographed on WATERS. " PREP-500 Hplc. The yield of the net above compound is 1.74 g
136 ° C crystalline change)
Example 16 (Al) -3- / ~ 4-Hydrazinosulfonyl) -phenyl7-52-one (R<sub>1</sub> -IHNH<sub>2</sub>, R.<sub>5</sub> = h)
<img file="GR77795B_D0026.tif" />
-2 3Rose of 3 g; <ck) -4 - / "5- (trifluoroacetoxymethyl) -2-oxooxazolid (,<sub>n</sub>_3-yl7-3 benzenesulfonyl chloride is added to a 5 ml solution of 300 ml hydrazine hydrate. tetrahydrofuran maintained at -10 to 0 ° C. After stirring for 30 minutes, the mixture was allowed to warm to room temperature. mp 172-4 ° C dec. The product is purified after being dissolved in 30 ml. The solution is filtered and diluted with CH2 OH, yield 8.8 g, m.p. 173 ° C, dec.
[0-7] (W (E -) - 4-Z'5- (acetoxymethyl) -2-oxoazazolidin-3-yl7-benzenesulfonamide. (R.<sub>1</sub> = NH<sub>2</sub>, R.<sub>5</sub> =00^)
A mixture of 19.3 g; (0.10 g / mL) (<1 g) -5- (hydroxymethyl) -3-phenyl2-oxazolidinone, 50 ml. CH ^ GN, 11 mL. acetic anhydride and 0.1 g.
4-Dimethylaminopyridine is boiled for 3 minutes. The mixture is concentrated in vacuo and crude oil is obtained, which is confirmed by IR and KMR to contain (d1) -5- (hydroxymethyl) -3-phenyl-2-oxoazazolidinone acetate.
The oil is added to 130 ml. Chlorosulphonic acid is stirred at room temperature for 2 hours at room temperature and then left to stand 3 liters of ice. The remaining oil is extracted with CHgClg and dried with Na<sub>2</sub>30 ^. The CHgClg is concentrated and the residual oil (10.9 g) is added to a 300 ml mixture. THF and 60 ml. dense NH ^, cooled to -10 ° to 0 ° C. The THF is removed in vacuo, and the residue is diluted with H<sub>2</sub>0 and filtered to yield 8.8 g of aqueous solution. 1 95.5-1 97 ° C. Recrystallization from CK <i> l yielded 6.3 g of the above compound, m.p. 199-2OO ° C.
Example 18
1-5-Hydroxymethyl-3-phenyl-2-oxazo, bisone M022-A
<img file="GR77795B_D0027.tif" />
-2 4 (R) - (+) - 1-Benzylglycerol (48 g or 0.263 g / g) is prepared by the methods of S.TAKAHO, 3. GOTO, I-i.iHRAriA and OGAEA's / iRA in HETEROCYCIES, 16, 381 (1981), and references cited herein.
This is stabilized by the above method and 57.8 g of brown oil is obtained.
A mixture of 37.1 g (0.1 5 g / l) of i-phenyl-4-methylhexenesulfonamide in 150 ml. Dry DME is stirred and 17 g of the compound is added. -t-butoxide of potassium, followed by 55 g of above tosylate. The mixture is heated to 95-1OO ° C for 15 hours. was washed with HgO and dried with HgSO to give 57.1 g. product. STOg thin-layer chromatography shows 3 components and little of the original sulfonanilium. Dissolve 57.1 g of the product in 1.5 liters of ether, stirring 100 ml. 25% aqueous LiOH, filtered through a layer of CELITE. The ether was concentrated to give 32.7 g. oil. These are chromatographed on SlOg columns and eluted with 99% toluene: 10% ethyl acetate in two cycles and 17.02 g are obtained. solid product, m.p. 88-99 ° C. The product is 4-methyl-N-phenyl A-hydroxy-3- (phenylmethoxy) -propyl7-benzenesulfonamide.
A solution of 16.5 g. (0.049 g) 4-Methyl-N-phenyl- / ~ 2-hydroxy-3- (phenylmethoxy) propyl7-benzenesulfonamide in 100 ml dry 1,2-dimethoxyethane is stirred with nitrogen anhydrous while adding anhydrous nitrogen sodium salt (prepared by adding 20 ml of a mineral metal suspension in mineral oil, to a solution of 4 g of naphthalene in 100 ml. of dry 1,2-dimethoxyethane, while the mixture is maintained at 25-40 ° C. Addition is continued until the color of the mixture has faded to dark green. At the end of the addition, the temperature is allowed to cool
<img file="GR77795B_D0028.tif" />
-25 After stirring for 50 minutes, 20 ml is added, followed by 125 ml. 20% H230 ° C. The temperature is maintained between 5 ° C-4 ° C during rinsing. 1,2-Dimethoxyethane is distilled off in vacuo. The HgO and the residue were extracted 6 times with toluene, 2 times with CHgClg and then transferred to nitrogen to remove the residue. The HgO is then saturated with NaCl and extracted 5 times with CHgClg. The extract is dried with anhydrous KgOO2, filtered and concentrated to give 40 g. The product is an amino c-5-phenyl </ - 1,2-propanediol.
Container 6.0 g. (0.056 g / d) d-5-phenylamino-1,2-propanediol is mixed with 10 ml. 1,2-dimethoxyethane and 5 ml of diethyl carbonate and boil. To the boiling solution is added 0.1 g. After 10 minutes the solid was removed and 5 ml more were added. The boiling was continued for 50 minutes, after which 1 ml was added. Acetic acid and the mixture were concentrated in vacuo, leaving 7.2 g of steroid. This was extracted with hot CH 2 OH and the CH 2 OH concentrated, yielding 1.8 g. of the above compound, m.p. 156.5-138 ° C. The optical rotation of product / g 7 is -67.1 ° (0 = 1 in OH + Cl)
Part B.
1820 ml of aniline is heated to 805 ° C. To this is slowly added 265 ml. freshly distilled glycidol at such a rate that the temperature is maintained at 85-90 ° C.
After adding the first 40-100 ml. of glycidol, the external heat source is removed and the reaction temperature is controlled by the rate of addition and eventual cooling. After the addition is complete, heat is applied to maintain for 2 hours. Product (s) -5-phenylamino-1 via a short column at a pressure of 4.0-4.5 mmHg, distilled at 5O-55 ° C (1.5 L, anh)
<img file="GR77795B_D0029.tif" />
-260.05 mm bp 132-5 ° C. Yield 588 g of viscous oil.
A solution of 1201 g. (7.18 g / g) (d) -3-Phenylamino-1,3-propanediol in 1.9 L of CHCl2 is stirred and 600.1 g is added.
(3.95 g / l) 1-almond acid. The mixture is heated to boiling to dissolve the solid. It is allowed to cool slowly, thereby crystallizing salt as crystals. GHGl ^ 3 times. * Dry yield was 068 g. (ΐ) -amygdalate (J) -3-phenylamino-1,2-propanediol, mp.86-7 ° 0. This is annealed by boiling with 2.8 L of CHCl2, cooled slowly and filtered, washed 3 times with CHCl. ^, whereby 754 g, m.p. 87 ° C.
- * ·*'·?
A suspension of 845 g of (ΐ) -amygdalate (o -) - 3-phenylamino-1,2-propanediol in 3 ml. H2 O is stirred in an ice bath, while a cold solution of 108 g is added. NaOH in 300 ml. The solution is saturated with NaCl and then extracted continuously with OHgGlp. The extract is concentrated in vacuo to give 446.9 g (<) of 3-phenylamino-1,2-propanediol, a colorless oil. is / ~ a 7<sup>=</sup> 23 ♦ 21 (0 = 1 in ethanol, transferred to a 200 cm tube.
A mixture of 441.5 g. (2.60 g / g) (3) - 3-Phenylamino-1,2-propanediol 325 ml 300 ml ethyl carbonate 300 ml 1,2-dimethoxyethane, 40 g. KpCl2, 1 g. Boil it for 2 hours. After this time another 20 grams are added. KrCo2. After 3.5 hours further diethyl carbonate is added. The boiling is continued for 15 hours. Thin layer chromatography shows that the reaction is keratized. Approximately half of the solvent is removed in vacuo and 500 ml is added. HPLC and 40 ml. CH ^ COOH. The white solid is filtered off and washed with H.<sub>?</sub>0, 70 g of ethanol and ether to obtain 4, 1.7; g / v of the above compound, m.p. 137.5-138; 5 ° C; Recrystallize from ethanol to obtain 368.1 g, m.p. 138 / £ xT39VJ<sup>THE</sup>0.·<sup>,</sup>Crystalline '' '' is made of 700 ml. GH_GIi whereby 330.4 g are obtained. 138.5-139.5 ° C
-2 7 * The optical rotation of the product / α_7 is -72.0 (C)<sup>=</sup>1 in GH ^ CN). Example 19 (3H) -4- ^ 1- (5- (Benzoyl-dimethyl) -2-oxoazazolidin-3-yl7-benzenesulfonamide (R)<sub>1</sub> = DD<sub>2</sub>, R.<sub>5</sub> = OC<sub>6</sub>H<sub>5</sub>)
A solution of 5.0 g. (18.3 g) (d) -4 - / "5- (droxymethyl) -2-oxoazazolidin-3-yl7-benzenesulfonamide in 5 g. The pyridine pellet is stirred at -8 ° C until cooled to 2.34 ml. An exothermic reaction is noted. Upon completion or addition, the mixture is allowed to warm to 25 ° C, and stirring is continued for 2 hours. A further 0.2 ml is added. benzoyl chloride and the mixture is left to stand overnight. The mixture is then ice-cold and the product crystallizes. Filter and wash thoroughly with HgO and dry. The yield is 6.72 g. This was recrystallized after dissolving in hot diethylene glycol dimethyl ether, concentrated to half the volume and allowed to stand, yield 3.55 g, m.p. 233-4 ° C.
Example 20 (A) -4- / 5- (propionyloxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonamide (R2) <sup>=</sup>KHg, R ^ "A solution of 5.0 g. (18.3 g / l) (g) -4- /<sup>_</sup>Of 50 (hydroxymethyl) -2oxoxoxazolidin-3-yl7-benzenesulfonamide in 50 ml. Pyridine powder is stirred in an ice bath while 1.60 ml is added. propionyl chloride. The mixture is allowed to warm to room temperature and left overnight. It is then drained to 200 ml. ice-HgO, HgO is acidified with HCl, kept cold, and the crystalline product is filtered and 212.5 ° C. This is recrystallized from nitromethane, thereby obtaining 3.22 g, m.p.
<img file="GR77795B_D0030.tif" />
c213.5.
Example 21 (ck) -butyanic acid, 4- / ~ 5- monoester with {- * cooled
-20gid yn-3-yl7-β with nesulosulfonamide Cd (R<sub>j</sub> - Eh<sub>2</sub>, R.<sub>5</sub> = C (O) CH<sub>2</sub>CH<sub>2</sub>COOH 'Solution 5.0 g. (18.3 g) (Jl) -4- / 25- (isosimethyl) -2ozoazazolidin-3-yl7-benzenesulfovimide in 50 ml. of pyridine and 2.02 g. Electric anhydride is stirred and heated at 60 ° C for 2 hours. The reaction mixture was poured into 100 ml of ice-H<sub>2</sub>0 and the pH is brought to 3 by the addition of concentrated HG1 (kept under cold).
The solution is saturated with NaCl and extracted with tetrahydrofuran.
The extract is dried with Na2O2 and concentrated to give 7.96 g. crystals. The solid was stirred in 50 ml of HCl<sub>2</sub>0 and, 20% KHCQ., is added, up to pH = 10.The product is then filtered and the filtrate is brought to pH = 2 with HCl. The product was filtered and dried, yielding 4.80 g, m.p. 167-17 ° C.
- <^ 7 '' - The sodium salt of this product is prepared if 2.4 g. this solid is dispersed in 50 ml. HgO, added 1N NaOH to pH = 7, filtered and concentrated in vacuo to give 2.35 g. white stereo.
In the same way, the following semi-esters O can be prepared
<img file="GR77795B_D0031.tif" />
The viscosity of the ionic ion<sup>R</sup>1 <sup>R</sup>5
Par
HjN-H
<img file="GR77795B_D0032.tif" />
Cl ^ i- H c = o (CH<sub>2</sub>)<sub>3</sub> I:
CO ^ a
N<sub>3</sub>H ^ l20
H
CHjNCM
H
CH ^ J0 n
<img file="GR77795B_D0033.tif" />
(CH<sub>3</sub>)<sub>2</sub>S = N- H
<img file="GR77795B_D0034.tif" />
(ch<sub>3</sub>)<sub>2</sub>s = nC0 * No *
<img file="GR77795B_D0035.tif" />
-30Example 28 'Ester of (ΐ) - /' 5- (Hydroxymethyl) -2-cocenzo; zolidin-3-yl7-benzenesulfonamide with L-alanine (S ^ = NHg, = 0005 (1 ^) OH ^ ) —7 .———————————————————————— - - - - - - - - - - - - - - - - -
If 1 / * The above compound can be prepared as follows: Solution 4.5 g. (0.02 g) K, N-dicyclohexylcarbodiimide in
GHgOlg is added to a solution of 5.4 g. (0.02 g) 1- / 5- (hydroxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonamide and 3.3 g (0.02 g) N-A-butoxycarbonyl-L-alanine, 1.2 g / kg 100 ml. GHgGlg. The mixture is stirred at room temperature for one day and the separated solids are filtered off. The filtrate is washed successively with 1M KHSO2, H2O and diluted with NaHCO2 and then dried with NagSO2. Dissolve the solid in 0 ° C at 0 ° C, stir for 15 minutes, and ether. Form a solid precipitate, filter, and wash with ether.
<img file="GR77795B_D0036.tif" />
<img file="GR77795B_D0037.tif" />
<img file="GR77795B_D0038.tif" />
<td></td><td>c. .join</td><td></td><td>Nt-BOC</td><td>t-product</td><td></td>
<td rowspan="2">Par</td><td><sup>R</sup>1</td><td> *5</td><td>AEOE</td><td><sup>R</sup>1</td><td><sup>R</sup>5</td>
<td></td><td></td><td></td><td></td><td>0 R</td>
<td> 29</td><td>CH-jHN-</td><td>H</td><td>Ph-CF ^ CHCO ^ t-BOC-NH</td><td>CHgW-</td><td>-CCH-CH<sub>9</sub>-Ph »* NH<sub>2</sub>0 H</td>
<td> 30</td><td>(CDjN-</td><td>H</td><td>t-BOCNHCH<sub>2</sub>OD<sub>2</sub>H</td><td>(Cl) ^ l-</td><td>-cch<sub>9</sub>t * nh<sub>2</sub>0 ft</td>
<td> 31</td><td><sup>N.</sup>3-</td><td>H</td><td>(ch<sub>3</sub>)<sub>2</sub>chchco<sub>2</sub>h t-BOC-NH</td><td><sup>N</sup>3-</td><td>-CCH<sub>2</sub>-CH (CH<sub>3</sub>)<sub>2</sub>™ 2 0 ft</td>
<td> 32</td><td>c<sub>2</sub>h<sub>5</sub>w-</td><td>H</td><td>(CH,), CHCH CHCO H t-BOC-NH</td><td>C<sub>2</sub>H<sub>5</sub>Ff4-</td><td>-CCH<sub>2</sub>CH<sub>2</sub>CH (CH<sub>3</sub>)<sub>2</sub>nh<sub>2</sub>0 ft</td>
<td> 33</td><td><sup>(CH</sup>3<sup>)</sup>2<sup>S = N</sup>‘</td><td>H</td><td>Ph-CH<sub>2</sub>CHC0<sub>2</sub>H t-BOC-NH</td><td>(CH<sub>3</sub>)<sub>2</sub>5 = N-</td><td>-CCH-CH ^ -Ph 1 NH<sub>2</sub>0 ft</td>
<td> 34</td><td>CH ^ OHN-</td><td>H</td><td>t-BOCNHCHjCOjH</td><td>CHjOFM-</td><td>-cch<sub>9</sub>1 * NH<sub>O</sub></td>
<img file="GR77795B_D0039.tif" />
-32Management forms:
The antibacterial agents of this invention can be administered in any manner by contacting the active agent with the region on which the agent acts on the body of a mammal. Whether as individual therapeutic agents or in a combination of therapeutic agents. They may be administered alone, but generally administered together with a pharmaceutical excipient,<sup>:</sup>whichever is chosen based on the route of administration selected and the standard pharmaceutical experience.
The dosage administered varies and is known to those skilled in the art. . ..
V factors, such as the pharmacodynamic characteristics of the particular agent, and the mode and route of administration, or age, health and weight of the patient, nature and extent of symptoms, type of concomitant treatment, frequency, or treatment with desired outcome or outcome. dose of active ingredient can be about 5-20 mg / kg body weight. Generally, when the most active compounds are used .. of this invention, 5-15, and preferably 5-7.5 mg / kg per day, administered in divided doses 2-4 times a day, or as a form of slow release, are sufficient to obtain the desired results. can also be administered parenterally.
Suitable forms of administration (preparations) for internal administration contain from about 1.0 mg to about 500 mg of the active ingredient unit. In these pharmaceutical preparations the active ingredient is generally present in an amount of about 0.5-95 g. -web calculation of the total weight of the preparation,
The active ingredient may be administered in a liquid form of administration, such as capsules, tablets for administration, such as olives, syrups and pills, and parenterally, as sterile liquid fluid.
<img file="GR77795B_D0040.tif" />
-33Gelatin capsules contain the active ingredient and powdered excipients, such as lactose, sucrose, mannitol, starch, cellulose derivatives I-ij stearate, nodule stearate and the like. Similar diluents can be used to make compressed tablets. Both capsules and tablets can be made as slow release products for continuous release of the drug over extended periods of time. taste, and to protect the tablet from the atmosphere, or enteric-coated coating for selective disintegration in the gastrointestinal tract.
Liquid forms of oral administration may use coloring and flavoring agents to increase or increase the receptivity of the patient.
Generally H 2 O, a suitable oil, physiological NaCl solution, aqueous dextrose (glucose) and related solutions of sugars and glycols, such as propylene glycol or polyethylene glycols, are suitable excipients for parenteral solutions, e.g. constituents, suitable stabilizers, and, if necessary, buffers. Suitable stabilizers are antioxidants, such as NaHSO ^, NagSO ^ or ascorbic, oz, either alone or in combination. ' Also used are citric acid and its salts and EPAA salt with sodium. Additional parenteral solutions may contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
<img file="GR77795B_D0041.tif" />
Suitable pharmaceutical excipients are described in REMIi7GT0K'S PHARMACEUTICAL 3GISN0ES, EW I-JAKTUI, a standard booklet in this field.
Useful pharmaceutical forms of the invention may be described as:
push her,.
-34Capsules:
A large number of capsule units are prepared if standard 2-piece hard gelatine capsules are filled or each with 75 mg. powdered actuator. component, 150 mg, lactose, 24 mg talc and 6 mg magnesium stearate.
A mixture of the active ingredient in soybean oil is prepared and injected with the aid of a special gelatin gel, to form soft gelatin capsules containing 75 mg. of the active ingredient. The capsules are washed with petroleum ether and dried.
Tablets:
A large number of tablets are prepared by conventional methods such that the unit dose is 75 mg of constituent, 0.2 mg of colloidal SiOg, 5 mg of magnesium tartarate, 250 mg of microcrystalline 'W' cellulose of 11 x 98 g. Appropriate coatings may be applied to increase or deliciousness - or to slow or absorb.
/ Opening:
A parenteral preparation suitable for administration by injection is prepared at 1.5% by weight. of active ingredient in 10% w / v. Propylene glycol in HgO is added. The solution is equilibrated with NaCl and sterilized.
Suspension An aqueous suspension for oral administration is prepared so that 5 ml of aqueous solution is administered. contain 75 mg of finely divided active ingredient, 200 mg of sodium carboxymethylcellulose, 5 mg of sodium benzoate, 1.0 g. of USP / ml sorbitol solution of p25 ml vanillin.
Experimental results show that the new associates
<img file="GR77795B_D0042.tif" />
i
-35efefresis are active against a wide variety of aerobic, anaerobic and binding dynamic anaerobic bacterial particles including strains that produce beta-lactamases, ETARIFIOOOO Cu3 AUREUS and Neisseria gonorrhea, members of negative GRAM Enterobacteriaceae ^ and ^ EUDOMONAS_AERUGINOSA. The anti-bacterial spectrum of these agents includes organisms that have been recognized as being highly pathogenic to humans and animals, including the respiratory, gastrointestinal, urogenital and central nervous system, the bloodstream, the intestines, the bloodstream, the intestines.
Table I presents a list of analogues showing in vitro inhibitory activity. A standard micro-dilution method (CONRATH, THEODORE B., 1972 HANDBOOK OF MICROTITER PROCEDURES, DYNATECH CORPORATION, CAMBRIDGE, MASSACHUSETTS) was used with nutrition;<sup>;</sup>MUELLER-HINTON suppressant material to determine 24-hour minimum inhibitory concentration (MIC) for strains of STAPHYLOCOCCUS EPIDERMIDI3 and E.COLI.
TABLE 1
IN VITRO minimum inhibitory concentrations in diluted nutrient ____ <sup>R</sup>1-°2<sup>3</sup>- \ O
OH
-1.
NH, £
NH,
Chemical designation
MIC dilution broth: µg / ml. S.EPIDERMIDIS E.COLI
N (CH<sub>5</sub>)<sub>2</sub>
CH ^ NH
GH ^ NH (3, ΐ) -4- / ~ 5- (hydroxymethyl) -2-oxoazazolidin-3-yl / benzenesulfonamide (ΐ) -4- / ~ 5- (hydroxymethyl) -2-ozoazazolidin-3-yl7 benzenesulfide <i, 1) -4 - / * "5- (hydroxymethyl) -2-oxoazazolidin-3-yl7-i (1,1-dlmethylbenzenesulsoonamide") 1) 5- (hydroxymethyl) -2-oxooxazolidin-3-yl7-N-methylbenzenesulfonamide "(1) -4 - / * 5- (hydroxymethyl) -2-thioxidine olidin-3-yl7- N -methylbenzenesulfono "mide" (3, ΐ) -4- / ~ 5- (hydroxymethyl) -2-oxooxazolidin-3-ylbenzenesulfonazide (ΐ) -4 - / "5- (hydroxymethyl) -2-oxooxazolidine Enzenesulfonylazide
62.5 62.5
31.3 31.3
<img file="GR77795B_D0043.tif" />
-36A Summary of IN VITRO Antibacterial Spectrum of (ΐ) -4 / ~ 5- (Hydroxymethyl) -2-Ozoxazolene In-3-yl7-βzenesulfonamide, is shown in Table II. Minimum Inhibitory Concentrations anaerobic experimental bacteria, representing 2 GRAM positive and 11 GRAM negative genes, were determined by agar dilution method. The method is typical in its kind and is as follows: LiUELLER-HINTON agar plates are prepared containing double concentrations of 128 µg / ml. up to 1.0 g / ml. for the susceptibility test of bacterial strains, with the exception of NEISSERIA GONORRHOEA and HEMOPHILUS SP. The latter organisms are tested using GO agar, containing 1% BAGT0-SUPPL3MENT C / DIPGO LABORATORIES, DETROIT, AND DETROIT. The agar plates were inoculated with 0.001 ml. standard (buffered) bacterial inoculum diluted to contain 5 X 10 ^ units capable of forming colonies (CFUs) per ml. After a 24-hour incubation at 35 ° C, MICs were recorded at low or minimal concentration of the compound, which inhibited macroscopic bacterial growth.
* The agar dilution method described by ALBARRY (THE ANTIMICROBIG SUSCEPTIBILITY TEST: PRINCIPLES AND PRACTICE 1976, LEA and FE3IGER, PHILADELPHIA, PENSYLVANIA) at concentrations of 32 µg / ml. up to 0.06 µg / ml. was used to determine or inhibit (ΐ) -4 - 5- "5- (hydroxymethyl) -2-oxooxazolidin3-yl7-benzenesulfonamide inhibitory activity for anaerobic bacteria.
<img file="GR77795B_D0044.tif" />
-37 TABLE II
IN_VITRO dichloroacetic acid (l) -4-Z'5 - (hydroxymethyl) -2-oxooxazolidin-3-yl7-benzenesulfonamide
<td>CONTROL ORGANIZATION NO.</td><td>PARTICLES</td><td>MEDIUM MIC<sup>1</sup>: µg / ml.</td>
<td>STAPHYLOCOCCUS SP.</td><td> 38</td><td> 22.3</td>
<td>STREPTOCOCCI SP</td><td> 14</td><td> 7.7</td>
<td>E.C0LI</td><td> 86</td><td> , 29.8</td>
<td>PROTEUS SP</td><td> 88</td><td> 29.1</td>
<td>PROVIDENCIA SP.</td><td> 12</td><td> 41.3</td>
<td>ENTEROBACTER SP</td><td> 41</td><td> 58.5</td>
<td>SALMONELLA SP</td><td> 6</td><td> 32</td>
<td>SHIGELLA SP.</td><td> 9</td><td> 8.0</td>
<td>3SRRATIA SP.</td><td> 44</td><td>£ 96.0 (range 32-> 128)</td>
<td>KLEBSIBLLA SP</td><td> 50</td><td> 39.4</td>
<td>PSEUDOMONAS SP.</td><td> 79</td><td>£ 116.8 (range 8- £ 128)</td>
<td>NEISSERIA SP.</td><td> 43</td><td> 12.3</td>
<td>HAEMOPHILUS SP.</td><td> 4</td><td> 32</td>
<td>CLOSTRIDIUM SP.</td><td> 5</td><td> 16.8</td>
<td>FUSOBAQTERIUM SP.</td><td> 4</td><td> 0.9</td>
<td>BACTER0IDE3 SP.</td><td> 23</td><td>£ 15.13 (£ 4- £ 32)</td>
<td>GRAM-ANAEROBIC COCCI</td><td> 7</td><td> 6.1</td>
<sup>1</sup>MIC: Minimum Inhibitory Concentration by Aging Dilution Method * The IN VIVO activity of these compounds is shown by the data summarized in Table III. in order to produce 90-100% mortality in control animals within 7 days. The diluents used are TRYPTICASE SOY BROTH for E<sub>L.</sub>00LI, seeded in 0.25% METHOCEL-H2O were administered by m.p.
n. xi ^ - ^ n * 3 »;,
PROTEUS SP. and PSEUDOMONAS AERUGINOSA and 5% HOG GASTRIC MUCIN for the infections of 3TAPHYLOCOCCUS_AUREUS. Compounds dissolved or bifurcated at the time of infection and again 4 hours of simulation are recorded every day until 50% at all times. ^ q with and / or sulfur ^ EB - ^ 'SPIRIT' (RE3B-38L.G and NUENCH. H., POINTS ”AMERICAN JOURNAL OF HYGIENE 27,1933, 493-497).
TABLE__III
IN WAY0_EFFECTIVE_COMMO_310_PRODUCTION_COM_<sub>L.</sub>
VANADIA_NE_Interpersonal<sub>></sub>_MOUSES_MOUSE
Chemical reaction, L (dl,) -4- / 75 - (hydroxymethyl) -2-ozozazolidin-3-ylbenzenesulfonamide 10 Chemical compound 2 (ΐ) -4 - / * 5- (hydroxymethyl) -2 -Ozooxazolidin-5-yl) -benzenesulfonamide Chemical compound 3
U, 1) -4-Z5 - (hydroxymethyl) -2-oxoazazolidin-3-yl) -benzenesulfonylazide.
Compound 4 (ΐ) -4- ^ ~ 5- (hydroxymethyl) -2-ozooxazo \ iv-5-yl7 ~ H -methylbenzenesulfonylazide V ΐ
Compound 5 (1) -4- / 5- (hydroxymethyl) -2-oxooxazolidin-5-yl7-N-methylbenzenesulfonate;
Bacterial bacterial organism
Chem.
STAPHYLO- ESCHERICHIA PROTEUS PROTEUS P3EUD0M0NAE COCCUS C01I MIRABILIS VULGARIS FLUORESCENS
AUREUS ----------- -------------'---- ---------- 5O<sup>1</sup>
ED—
ED '50
ED,
NHg
NHg
N_ n>
£9.1
33.4 25.99
26.4
24.9
13.9 17.89 14.87
NT?
44.3
NT
NT
ED
NT
40.8
NT
NT
ED,
NT
67.46
NT
NT
Contents37
44 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44
33 members in 19 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 32758381 | United States of America | A | |
| 32758381 | United States of America | A | |
| 41756982 | United States of America | A | |
| 41756982 | United States of America | A | |
| 327583 | – | – | – |
| 417569 | – | – | – |
| US19810327583 | – | – | – |
| US19820417569 | – | – | – |
Members33
| Document | Office | Kind | |
|---|---|---|---|
| FI824182A0 | Finland | A0 | |
| PT75928A | Portugal | A | |
| IL67397A0 | Israel | A0 | |
| IL67397D0 | Israel | D0 | |
| DK538382A | Denmark | A | |
| FI824182L | Finland | L | |
| NO824072L | Norway | L | |
| AU9103282A | Australia | A | |
| EP0081200A1 | European Patent Office (EPO) | A1 | |
| JPS58103376A | Japan | A | |
| ES517852A0 | Spain | A0 | |
| ES8401951A1 | Spain | A1 | |
| US4461773A | United States of America | A | |
| ZA828872B | South Africa | B | |
| GR77795BThis record | Greece | B | |
| NZ202695A | New Zealand | A | |
| CA1182824A | Canada | A | |
| HU186807B | Hungary | B | |
| SU1194274A3 | Soviet Union (until 1991) | A3 | |
| PT75928B | Portugal | B | |
| HU189196B | Hungary | B | |
| EP0081200B1 | European Patent Office (EPO) | B1 | |
| AT22686T | Austria | T | |
| ATE22686T1 | Austria | T1 | |
| DE3273626D1 | Germany | D1 | |
| IL67397A | Israel | A | |
| AU560666B2 | Australia | B2 | |
| NO156751B | Norway | B | |
| NO156751C | Norway | C | |
| MX155630A | Mexico | A | |
| FI78078B | Finland | B | |
| FI78078C | Finland | C | |
| JPH0416471B2 | Japan | B2 |
Numbers
- Publication, DOCDB
- 77795
- Publication, EPODOC
- GR77795
- Application
- 69986
- Application, DOCDB
- 820169986
- Application, EPODOC
- GR19820169986
Titles
- English
- P-OXOOXAZOLIDINYLBENZENE SULFONAMIDES AS ANTIBACTERIAL AGENTS
Classification
- CPC, 2
- C07D263/24
- A61P3/04
- IPC, 3
- A61K31 421
- A61P3 04
- C07D263 24